BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22370677)

  • 1. Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins.
    Sheffield WP; Eltringham-Smith LJ; Bhakta V; Gataiance S
    Thromb Haemost; 2012 May; 107(5):972-84. PubMed ID: 22370677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition.
    Sutherland JS; Bhakta V; Filion ML; Sheffield WP
    Biochemistry; 2006 Sep; 45(38):11444-52. PubMed ID: 16981704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
    Sutherland JS; Bhakta V; Sheffield WP
    Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition.
    Roddick LA; Bhakta V; Sheffield WP
    BMC Biochem; 2013 Nov; 14():31. PubMed ID: 24215622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
    Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
    Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The M358R variant of α(1)-proteinase inhibitor inhibits coagulation factor VIIa.
    Sheffield WP; Bhakta V
    Biochem Biophys Res Commun; 2016 Feb; 470(3):710-713. PubMed ID: 26797521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined administration of barbourin--albumin and hirudin--albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta.
    Sheffield WP; Gataiance S; Eltringham-Smith LJ
    Thromb Res; 2007; 119(2):195-207. PubMed ID: 16478628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retention of thrombin inhibitory activity by recombinant serpins expressed as integral membrane proteins tethered to the surface of mammalian cells.
    Gierczak RF; Sutherland JS; Bhakta V; Toltl LJ; Liaw PC; Sheffield WP
    J Thromb Haemost; 2011 Dec; 9(12):2424-35. PubMed ID: 21972922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
    Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.
    Xu Y; Cai TQ; Castriota G; Zhou Y; Hoos L; Jochnowitz N; Loewrigkeit C; Cook JA; Wickham A; Metzger JM; Ogletree ML; Seiffert DA; Chen Z
    Thromb Haemost; 2014 Apr; 111(4):694-704. PubMed ID: 24336918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression screening of bacterial libraries of recombinant alpha-1 proteinase inhibitor variants for candidates with thrombin inhibitory capacity.
    Bhakta V; Gierczak RF; Sheffield WP
    J Biotechnol; 2013 Dec; 168(4):373-81. PubMed ID: 24140600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-1 proteinase inhibitor M358R reduces thrombin generation when displayed on the surface of cells expressing tissue factor.
    Gierczak RF; Pepler L; Bhagirath V; Liaw PC; Sheffield WP
    Thromb Res; 2014 Nov; 134(5):1142-9. PubMed ID: 25242242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
    Suleymanov OD; Szalony JA; Salyers AK; LaChance RM; Parlow JJ; South MS; Wood RS; Nicholson NS
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1115-21. PubMed ID: 12829728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of mammalian and bacterial expression library screening to detect recombinant alpha-1 proteinase inhibitor variants with enhanced thrombin inhibitory capacity.
    Gierczak RF; Bhakta V; Xie M; Sheffield WP
    J Biotechnol; 2015 Aug; 208():54-62. PubMed ID: 26043905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant.
    Hamada M; Bhakta V; Andres SN; Sheffield WP
    Front Cardiovasc Med; 2021; 8():647405. PubMed ID: 33816577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis.
    Bhakta V; Hamada M; Nouanesengsy A; Lapierre J; Perruzza DL; Sheffield WP
    Sci Rep; 2021 Mar; 11(1):5565. PubMed ID: 33692375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.